Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab for treatment of high-risk, early-stage triple-negative breast cancer: A network meta-analysis - Cortes, J.; Haiderali, A.; Huang, M.; Pan, W.; Fox, G. E.; Park, J.; Frederickson, A. M.; Fasching, Peter; O'Shaughnessy, J. (ANNALS OF ONCOLOGY, 2022)
CRIS-Team WoS Importer:2022-12-23